Avirmax Biopharma to Present Groundbreaking Research at ARVO
Avirmax Inc. is set to make waves at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting this year. With three significant scientific presentations scheduled, Avirmax is eager to showcase its innovative research in ocular gene therapy.
Key Presentations by Avirmax
Dr. Shengjiang Liu, the Chief Executive and Scientific Officer, will present at the event, shedding light on their cutting-edge VSaf™ AAV platform technology. This impressive presentation titled "A Fast and Robust VSaf™ AAV Platform Technology for Producing High Quality and Yield of AAV Vectors for Ocular Gene Therapy" will occur at the Paper Presentation venue on May 7.
The company has another engaging session titled "Protective Efficacy of ABI-201 in a Sodium Iodate-Induced Retinal Damage Model of Dry AMD in Non-Human Primates". This oral presentation by Sameera Peraramelli, Ph.D., will explore new avenues for treating dry AMD during the AMD Translational Studies session.
Focus on Advancements in Retinal Research
A third highlighted session, "Advancing Retinal Disease Research: The Sodium Iodate NHP Model for Translational Therapeutic Evaluation," will further illustrate the relevance of their innovative approaches, providing insights into ongoing developments and potential therapeutic outcomes. This exhibitor lounge presentation is scheduled for May 4, ensuring robust discussions among attendees.
Avirmax Biopharma's commitment to ocular gene therapy continues to demonstrate real potential in treating vision-related ailments, especially with their candidate ABI-201, which carries three functional genes specifically aimed at addressing dry AMD. Their sodium iodate-induced non-human primate (NHP) model is crucial for validating their approach and enhancing progress within their pipeline.
Exhibition at the Event
In addition to these presentations, Avirmax will proudly exhibit their latest research findings. Visitors can learn more about their cutting-edge advancements in ocular therapies at Booth #1008. This exhibition will allow attendees to dive deeper into Avirmax’s innovative technology and how it aims to serve patients effectively.
About Avirmax Inc.
Avirmax Biopharma Inc. is renowned for its work in developing rAAV-mediated therapeutics, focusing on ocular diseases through its advanced AAV engineering technologies and production methodologies. The company is committed to creating accessible and affordable gene therapy solutions to meet patient needs.
For additional insights and information about Avirmax Biopharma, you can visit their official website for comprehensive resources and updates.
Frequently Asked Questions
What is the purpose of Avirmax’s presentations at ARVO?
The presentations aim to showcase advancements in ocular gene therapy and demonstrate their unique research in addressing conditions like dry AMD.
Who will present at the ARVO annual meeting?
Dr. Shengjiang Liu, along with Sameera Peraramelli, Ph.D., will deliver key presentations highlighting Avirmax's innovative research.
What is ABI-201?
ABI-201 is a therapeutic candidate developed by Avirmax, designed to treat dry AMD by carrying three functional genes using AAV vectors.
Where can attendees learn more about Avirmax’s innovations?
Attendees can explore Avirmax's latest advancements at their exhibition booth #1008 during the ARVO annual meeting.
What is the significance of the sodium iodate NHP model?
The sodium iodate NHP model is significant for validating therapeutic approaches to dry AMD and demonstrating translational relevance in research.
